跳至主要内容
临床试验/NCT05917821
NCT05917821尚未招募不适用

Identification of New Antigens Against Glioblastoma

Fondazione Policlinico Universitario Agostino Gemelli IRCCS0 个研究点目标入组 120 人开始时间: 2023年8月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
120
主要终点
Validation of the tumour specificity of the identified monoclonal antibodies

研究概览

简要总结

In this study the investigators will select and develop potential therapeutic monoclonal antibodies (mAbs) for glioblastoma (GB). Activities include tissue microarray (TMA) to test monoclonal antibodies specificity and target distribution, selection of glioblastoma specific functional monoclonal antibodies, identification of candidate targets.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age > 18 years;
  • Written informed consent

排除标准

  • Not-availability of informed consent

结局指标

主要结局

Validation of the tumour specificity of the identified monoclonal antibodies

时间窗: 4 years

Candidate monoclonal antibodies will be tested by immunohistochemistry (IHC) on sections of glioblastoma tissue and healthy counterpart.

次要结局

  • Generate the single chain Fab antibody fragments (scFv) and then develop the Chimeric Antigen Receptor (CAR) T cells(4 years)

研究者

申办方类型
Other
责任方
Sponsor

相似试验